• Experience Exchang •
Therapeutic effects of radiofrequency ablation for hepatocellular carcinoma: Evaluated by magnetic resonance imaging
Cite this article as: Ming ZQ, Cao JM, Chen TW, et al. Therapeutic effects of radiofrequency ablation for hepatocellular carcinoma: Evaluated by magnetic resonance imaging[J]. Chin J Magn Reson Imaging, 2022, 13(5): 115-119. DOI:10.12015/issn.1674-8034.2022.05.021.
| [Abstract] Objective To investigate the feasibility of magnetic resonance imaging (MRI) in evaluating different therapeutic effects of radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC).Materials and Methods From January 2018 to June 2021, 52 HCC patients with a total of 60 lesions treated by RFA from Affiliated Hospital of North Sichuan Medical College underwent MRI plain scan, multiphase enhanced scans, and diffusion weighted imaging (DWI) before the previous treatments and were regularly followed up after this therapy, and the MRI data were retrospectively collected. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of MRI for detecting complete ablation, tumor residual, local tumor progression and new tumor were statistically calculated.Results (1) For showing complete ablation, the sensitivity, specificity, PPV, NPV and accuracy of MRI were 89.5%, 92.7%, 85.0%, 95.0% and 91.7%, respectively; (2) For detecting tumor residual, the sensitivity, specificity, PPV, NPV and accuracy of MRI were 81.8%, 91.8%, 69.2%, 95.7% and 90.0%, respectively; (3) For demonstrating local tumor progression after RFA, the sensitivity, specificity, PPV, NPV and accuracy of follow-up MRI were 84.6%, 93.2%, 78.6%, 95.3% and 91.2%, respectively; (4) For demonstrating new tumor in liver after RFA, the sensitivity, specificity, PPV, NPV and accuracy of follow-up MRI were 100.0%, 94.7%, 88.9%, 100.0% and 96.3%, respectively.Conclusions When MRI is used to evaluate the efficacy of RFA of HCC, it has a very good potential on the detection of complete ablation, tumor residual, local tumor progression and new tumor in liver, especially of complete ablation and new tumor in liver. |
| [Keywords] hepatocellular carcinoma；radiofrequency ablation；efficacy evaluation；magnetic resonance imaging；diffusion weighted imaging |
MING Zhiqiang1,
2
CAO Jinming3
CHEN Tianwu1*
WU Yuping1
YANG Liqin3
GAO Dan1
1 Department of Radiology, Affiliated Hospital of North Sichuan Medical College, Sichuan Key Laboratory of Medical Imaging Nanchong 637000, China
2 Department of Radiology, Zigong First People's Hospital, Zigong 643000 China
3 Department of Radiology, Nanchong Central Hospital, Second School of Clinical Medicine, North Sichuan Medical College, Nanchong 637000, China
Chen TW, E-mail: tianwuchen_nsmc@163.com
Conflicts of interest None.
| ACKNOWLEDGMENTS National Natural Science Foundation of China (No. 81050033). |
| Received 2021-11-08 |
| Accepted 2022-04-22 |
| DOI: 10.12015/issn.1674-8034.2022.05.021 |
| Cite this article as: Ming ZQ, Cao JM, Chen TW, et al. Therapeutic effects of radiofrequency ablation for hepatocellular carcinoma: Evaluated by magnetic resonance imaging[J]. Chin J Magn Reson Imaging, 2022, 13(5): 115-119. DOI:10.12015/issn.1674-8034.2022.05.021. |
[1]
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
DOI:
10.3322/caac.21492.
[2]
Zhou MG, Wang HD, Zeng XY, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158.
DOI:
10.1016/S0140-6736(19)30427-1.
[3]
National Health Commission of the People's Republic of China Medical Administration and Hospital Administration. Standardization for diagnosis and treatment of hepatocellular carcinoma (2019 edition)[J]. Chin J Dig Surg, 2020, 19(1): 1-20.
DOI:
10.3760/cma.j.issn.1673-9752.2020.01.001.
[4]
Jia Z, Zhang HT, Li N. Evaluation of clinical outcomes of radiofrequency ablation and surgical resection for hepatocellular carcinoma conforming to the Milan criteria: a systematic review and meta-analysis of recent randomized controlled trials[J]. J Gastroenterol Hepatol, 2021, 36(7): 1769-1777.
DOI:
10.1111/jgh.15440.
[5]
Lee DH, Lee MW, Kim PN, et al. Outcome of no-touch radiofrequency ablation for small hepatocellular carcinoma: a multicenter clinical trial[J]. Radiology, 2021, 301(1): 229-236.
DOI:
10.1148/radiol.2021210309.
[6]
Lei JY, Yan LN, Li DJ, et al. Comparison of open liver resection and RFA for the treatment of solitary 3-5-cmhepatocellular carcinoma: a retrospective study[J]. BMC Surg, 2019, 19(1): 195.
DOI:
10.1186/s12893-019-0663-9.
[7]
Ren YQ, Zheng CS. Different imaging assessments for hepatocellular carcinoma after radiofrequency ablation: clinical application and recent progress[J]. J Interv Radiol, 2018, 27(10): 993-996.
[8]
Ming ZQ, Cao JM, Chen TW. CT evaluation of radiof requency ablation for hepatocellular carcinoma[J]. Med J West China, 2021, 33(5): 764-770.
DOI:
10.3969/j.issn.1672-3511.2021.05.030.
[9]
Zheng JS, Fan WJ, Hu KW, et al. Expert consensus on standardized clinical application of image-guided thermal ablation of liver tumor[J]. J Clin Hepatology, 2017, 33(10): 1864-1869.
DOI:
10.3969/j.issn.1001-5256.2017.10.004.
[10]
Llovet JM, Lencioni R. mRECIST for HCC: performance and novel refinements[J]. J Hepatol, 2020, 72(2): 288-306.
DOI:
10.1016/j.jhep.2019.09.026.
[11]
Qu JR, Liu CC, Zhang HK, et al. Comparison of computed tomography versus magnetic resonance imaging in assessing radiofrequency ablation margins after radiofrequency ablation in patients with hepatocellular carcinomas[J]. Acta Acad Med Sin, 2012, 34(5): 480-485.
DOI:
10.3881/j.issn.1000-503X.2012.05.008.
[12]
Xiao B, Wang CY, Cao Y, et al. A comparative study of contrast-enhanced ultrasonograpgy versus contrast-enhanced CT in evaluating short-term efficacy of percutaneous radiofrequency ablation for hapatic carcinoma[J]. Guangxi Med J, 2015, 37(7): 931-934.
DOI:
10.11675/j.issn.0253-4304.2015.07.15.
[13]
Zhang ZJ, Wu MC, Liu Q, et al. Imaging evaluation of efficacy of radiofrequency ablation treatment for hepatic cancer[J]. Chin J Oncol, 2005, 27(10): 616-619.
DOI:
10.3760/j.issn:0253-3766.2005.10.011.
[14]
Tao YY, Zhou Y, Wang R, et al. Progress of intravoxel incoherent motion diffusion-weighted imaging in liver diseases[J]. World J Clin Cases, 2020, 8(15): 3164-3176.
DOI:
10.12998/wjcc.v8.i15.3164.
[15]
Xie DY, Ren ZG, Zhou J, et al. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights[J]. Hepatobiliary Surg Nutr, 2020, 9(4): 452-463.
DOI:
10.21037/hbsn-20-480.
[16]
Ming ZQ, Hu XL, Chen TW. Therapeutic effects of radiofrequency ablation for hepatocellular carcinoma evaluated by CT and MRI: the current status[J]. Int J Med Radiol, 2021, 44(6): 692-697.
DOI:
10.19300/j.2021.Z18897.
[17]
Jin S, Tan SS, Peng W, et al. Radiofrequency ablation versus laparoscopic hepatectomy for treatment of hepatocellular carcinoma: a systematic review and meta-analysis[J]. World J Surg Oncol, 2020, 18(1): 199.
DOI:
10.1186/s12957-020-01966-w.
[18]
Wang J, Yang SJ, Li Y. The value of magnetic resonance imaging in evaluating the efficacy of radiofrequency ablation for primary liver cancer[J]. Chin J Med Imaging, 2020, 4(15): 18-20.
DOI:
10.3969/j.issn.2096-3807.2020.15.010.
[19]
Kobe A, Kindler Y, Klotz E, et al. Fusion of preinterventional MR imaging with liver perfusion CT after RFA of hepatocellular carcinoma: early quantitative prediction of local recurrence[J]. Invest Radiol, 2021, 56(3): 188-196.
DOI:
10.1097/RLI.0000000000000726.
[20]
Keller S, Chapiro J, Brangsch J, et al. Quantitative MRI for assessment of treatment outcomes in a rabbit VX2 hepatic tumor model[J]. J Magn Reson Imaging, 2020, 52(3): 668-685.
DOI:
10.1002/jmri.26968.
[21]
Tang J, Li JF, Liu FY, et al. The progress and advance on diffusion-weighted imaging in locoregional interventional treatment of hepatocellular carcinoma[J]. Chin J Hepatobiliary Surg, 2021, 27(3): 235-240.
DOI:
10.3760/cma.j.cn113884-20200511-00259.
[22]
Wang DD, Li XG. Residual tumor after radiofrequency ablation of hepatocellular carcinoma: its current situation and research progress[J]. J Interv Radiol, 2019, 28(8): 800-804.
DOI:
10.3969/j.issn.1008-794X.2019.08.021.
[23]
Koda M, Tokunaga S, Miyoshi K, et al. Assessment of ablative margin by unenhanced magnetic resonance imaging after radiofrequency ablation for hepatocellular carcinoma[J]. Eur J Radiol, 2012, 81(10): 2730-2736.
DOI:
10.1016/j.ejrad.2011.11.013.
[24]
Yin N, Guo Z, Fu JF, et al. Evaluation of local efficacy of ablation of liver tumor on 3.0 T MRI and CT[J]. Mod Med J, 2020, 48(3): 311-316.
DOI:
10.3969/j.issn.1671-7562.2020.03.005.
[25]
Granata V, Grassi R, Fusco R, et al. Abbreviated MRI protocol for the assessment of ablated area in HCC patients[J]. Int J Environ Res Public Health, 2021, 18(7): 3598.
DOI:
10.3390/ijerph18073598.
[26]
Rimola J, Forner A, Sapena V, et al. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma[J]. Eur Radiol, 2020, 30(1): 186-194.
DOI:
10.1007/s00330-019-06351-0.
[27]
Tang J, Liu FY, Yuan HJ, et al. Pretreatment apparent diffusion coefficient as a predictor of response to transcatheter arterial chemoembolization immediately combined with radiofrequency ablation for treatment of solitary large hepatocellular carcinoma[J]. Cancer Manag Res, 2020, 12: 10127-10138.
DOI:
10.2147/CMAR.S270470.
